2 articles published in JoVE
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology Detection of minimal or measurable residual disease (MRD) is an important prognostic biomarker for refining risk assessment and predicting relapse in acute myeloid leukemia (AML). These comprehensive guidelines and recommendations with best practices for consistent and accurate identification and detection of MRD, may aid in making effective AML treatment decisions.
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models Rocco Sciarrillo1,2,3, Anna Wojtuszkiewicz1, Irsan E. Kooi4, Valentina E. Gómez3, Ugo Boggi5, Gerrit Jansen6, Gert-Jan Kaspers1,7, Jacqueline Cloos*1, Elisa Giovannetti*3,8,9 1Department of Pediatric Oncology/Hematology, VU University Medical Center, 2Department of Hematology, VU University Medical Center, 3Department of Medical Oncology, VU University Medical Center, 4Department of Clinical Genetics, VU University Medical Center, 5Division of General and Transplant Surgery, Azienda Ospedaliera Universitaria Pisana, Universita’ di Pisa, 6Amsterdam Immunology and Rheumatology Center, VU University Medical Center, 7Princess Máxima Center for Pediatric Oncology, 8Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, 9Institute of Nanoscience and Nanotechnology, CNR-Nano Here we describe a protocol aimed at investigating the impact of aberrant splicing on drug resistance in solid tumors and hematological malignancies. To this goal, we analyzed the transcriptomic profiles of parental and resistant in vitro models through RNA-seq and established a qRT-PCR based method to validate candidate genes.